Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch: Bridgebio’s Endpoint A Bridge Too Far

Switch From Surrogate To Clinical Endpoint Between Phase II and III Had Big Risks

Executive Summary

The news desert over the holidays meant that any Phase III clinical study announcement would be closely examined. Unfortunately, BridgeBio’s shock Phase III failure was made worse by elusive explanations.

You may also be interested in...



Finance Watch: Bausch + Lomb Completes Split From Bausch Health Via IPO

Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.

Alnylam Confident It Won’t Stumble On ATTR Trial Like BridgeBio

Alnylam expects success in its Phase III study in amyloid cardiomyopathy- but a competitor’s baffling failure is making analysts jittery.

Intellia To Take On Pfizer Blockbuster With Gene-Editing Therapy

After achieving a landmark in gene-editing with NTLA-2001, Intellia moves to expand its reach into a larger market.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145646

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel